Q1 2026 saw lower sales and a wider loss amid a strategic shift toward CRO services and commercial scalability. A key patent was approved, a pilot project showed promise, and a rights issue is planned to strengthen finances.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.